Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
rTMS in resistant mixed states: an exploratory study.
Pallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. Pallanti S, et al. Among authors: antonini s. J Affect Disord. 2014 Mar;157:66-71. doi: 10.1016/j.jad.2013.12.024. Epub 2013 Dec 28. J Affect Disord. 2014. PMID: 24581830
Low-frequency rTMS over right dorsolateral prefrontal cortex in the treatment of resistant depression: cognitive improvement is independent from clinical response, resting motor threshold is related to clinical response.
Pallanti S, Di Rollo A, Antonini S, Cauli G, Hollander E, Quercioli L. Pallanti S, et al. Among authors: antonini s. Neuropsychobiology. 2012 Jun;65(4):227-35. doi: 10.1159/000336999. Epub 2012 May 25. Neuropsychobiology. 2012. PMID: 22653158
Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Pallanti S, et al. Among authors: antonini s. Eur Neuropsychopharmacol. 2014 Mar;24(3):375-80. doi: 10.1016/j.euroneuro.2013.12.003. Epub 2013 Dec 11. Eur Neuropsychopharmacol. 2014. PMID: 24406025 Clinical Trial.
Facial affect recognition in CADASIL patients.
Valenti R, Salvadori E, Pescini F, Poggesi A, Castellini G, Antonini S, Bianchi S, Inzitari D, Pallanti S, Pantoni L. Valenti R, et al. Among authors: antonini s. Arch Clin Neuropsychol. 2013 Feb;28(1):65-71. doi: 10.1093/arclin/acs097. Epub 2012 Nov 4. Arch Clin Neuropsychol. 2013. PMID: 23127883
International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.
Riedmeier M, Antonini SRR, Brandalise S, Costa TEJB, Daiggi CM, de Figueiredo BC, de Krijger RR, De Sá Rodrigues KE, Deal C, Del Rivero J, Engstler G, Fassnacht M, Fernandes Luiz Canali GC, Molina CAF, Gonc EN, Gültekin M, Haak HR, Guran T, Hendriks Allaird EJ, Idkowiak J, Kuhlen M, Malkin D, Meena JP, Pamporaki C, Pinto E, Puglisi S, Ribeiro RC, Thompson LDR, Yalcin B, Van Noesel M, Wiegering V. Riedmeier M, et al. Among authors: antonini srr. Eur J Endocrinol. 2024 Mar 30;190(4):G15-G24. doi: 10.1093/ejendo/lvae038. Eur J Endocrinol. 2024. PMID: 38552173
Low PRKAB2 Expression Is Associated with Poor Outcomes in Pediatric Adrenocortical Tumors, and Treatment with Rottlerin Increases the PRKAB2 Level and Inhibits Tumorigenic Aspects in the NCI-H295R Adrenocortical Cancer Cell Line.
Xavier AET, Veronez LC, Nagano LFP, Correa CAP, Baroni M, Ramos MS, Queiroz RGP, Fernandes Molina CA, Yunes JA, Brandalise SR, Antonini SAR, Tone LG, Valera ET, Scrideli CA. Xavier AET, et al. Among authors: antonini sar. Cancers (Basel). 2024 Mar 8;16(6):1094. doi: 10.3390/cancers16061094. Cancers (Basel). 2024. PMID: 38539429 Free PMC article.
186 results